LAUSR

J Med 2018;378:829–839. 3. Palevsky PM, Molitoris BA, Okusa MD, Levin A, Waikar SS, Wald R, et al. Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodology. Clin J Am Soc Nephrol 2012;7: 844–850. 4. McKown AC, Wang L, Wanderer JP, Ehrenfeld J, Rice TW, Bernard GR, et al. Predicting major adverse kidney events among critically ill adults using the electronic health record. J Med Syst 2017; 41:156. 5. Vincent J-L, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22: 707–710. 6. Segal JB, Weiss C, Varadhan R. Understanding heterogeneity of treatment effects in pragmatic trials with an example of a large, simple trial of a drug treatment for osteoporosis. Center for Medical Technology Policy; 2011 [accessed 2018 Aug 10]. Available from: http://www.cmtpnet.org/docs/resources/Segal-Heterogeneityin-Pragmatic-Trials.pdf.